Notably, acquired resistance to osimertinib exhibits adaptive downregulation of FUNDC1, rendering resistant EGFR-mutant NSCLC cells more sensitive to nitidine. The gene discussed is FUNDC1; the disease is non-small cell lung carcinoma.